Seribantumab (Merrimack Pharmaceuticals) is a monoclonal antibody directed against human epidermal growth factor receptor 3 (HER3).
Singulair (montelukast; Merck & Co/Kyorin) is an oral leukotriene D4 receptor antagonist used for prophylactic treatment of asthma. The drug is available in several oral formulations and is primarily taken as an add-on therapy for patients with refractory and/or allergic asthma.
Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a single-tablet regimen (STR) approved for the treatment of HIV-1 infection.
Cebranopadol is a novel small molecule analgesic, which was discovered by Grünenthal. Cebranopadol represents a novel, first-in-class potent analgesic that has a dual mechanism of action as a potent agonist of both the nociceptin/orphanin FQ peptide receptor (NOP) and opioid peptide receptor.
MIN-101 (Minerva Neurosciences/Mitsubishi Tanabe) is a novel antagonist of the sigma-2 and serotonin 5-HT2A receptors.
Trelstar (triptorelin; Allergan) is a gonadotropin-releasing hormone (GnRH) receptor agonist which acts on the pituitary gland to stimulate luteinizing hormone (LH) release, resulting in a temporary surge in serum testosterone levels known as “flare.”
Cyramza (ramucirumab; Eli Lilly/Shire) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of VEGFR-2 found on tumor vasculature.
Bempedoic acid is an orally administered small molecule that inhibits fatty acid and cholesterol synthesis.
Encorafenib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is a RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAF V600E.
Talzenna (talazoparib; Pfizer) is a small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP). PARP inhibitors block the activity of PARP, an enzyme that plays an essential role in DNA repair mechanisms and homologous recombination events, by directly blocking enzymatic activity, or by causing PARP to accumulate on DNA (PARP trapping), which results in DNA replication inhibition and cell death.
Trelegy Ellipta ([fluticasone furoate + vilanterol + umeclidinium bromide]; GlaxoSmithKline) is a fixed triple combination inhaled corticosteroid/long-acting beta 2 agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) therapy.
Nucala (mepolizumab; GlaxoSmithKline) is a humanized monoclonal immunoglobulin G1 antibody that binds to interleukin (IL)-5, which plays a significant role in the activation, proliferation, and differentiation of eosinophils.
AbbVie’s Duopa, a continuous intestinal infusion of a carbidopa plus levodopa gel, is indicated for the treatment of advanced-stage idiopathic Parkinson’s disease with motor fluctuations that cannot be treated with oral therapies.
Boehringer Ingelheim will hope to increase Vargatef’s (nintedanib) market share at second-line despite
rising competition in this setting.
Ixempra (ixabepilone; R-Pharm/Otsuka) is a lactam analog of epothilone B that binds to microtubules via tubulin.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!